Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement
about
Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerManagement of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment optionsReview of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrantClinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.EPMA position paper in cancer: current overview and future perspectives.Treatment Considerations for the Management of Patients With Hormone Receptor-Positive Metastatic Breast Cancer.Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.The Estrogen Receptors: An Overview from Different Perspectives.Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer.Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects.
P2860
Q26770482-C1EF676C-DB07-40EA-9CF5-1E239437A292Q26995549-531E1E76-F7CB-48AD-A130-AC51E79DAF4FQ28076777-1BB5303E-B62D-47DC-A707-FA822FA5BAD2Q34362184-DB44C23F-AA4E-46B4-811D-C9B035B7B596Q35532215-B40B445A-0707-4976-8E2F-83B4020B8488Q35687540-993DA517-C7DA-410E-B62F-599D3F272131Q37534910-38E9F82A-9A99-49E7-B319-9245A0578855Q38638935-B5568045-6C0A-4803-858F-DBB35FA40EF9Q39172983-E6E28879-8F42-4C29-BF5D-00E1BC6A3655Q46475664-A8E38269-3D14-4B5A-A327-580FBB1BEE71Q55090991-C63AEE9C-149B-453E-B27C-022E410AAB9B
P2860
Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Endocrine therapy for postmeno ...... a Canadian consensus statement
@ast
Endocrine therapy for postmeno ...... a Canadian consensus statement
@en
type
label
Endocrine therapy for postmeno ...... a Canadian consensus statement
@ast
Endocrine therapy for postmeno ...... a Canadian consensus statement
@en
prefLabel
Endocrine therapy for postmeno ...... a Canadian consensus statement
@ast
Endocrine therapy for postmeno ...... a Canadian consensus statement
@en
P2093
P2860
P356
P1433
P1476
Endocrine therapy for postmeno ...... a Canadian consensus statement
@en
P2093
K A Gelmon
K I Pritchard
L Provencher
P2860
P356
10.3747/CO.20.1316
P577
2013-02-01T00:00:00Z